Geron (NASDAQ:GERN) Sets New 52-Week Low - Here's Why

Geron Co. (NASDAQ:GERN - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $1.46 and last traded at $1.59, with a volume of 30525697 shares. The stock had previously closed at $2.37.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GERN. HC Wainwright cut Geron from a "buy" rating to a "neutral" rating in a research report on Wednesday. Barclays reiterated an "overweight" rating and issued a $4.00 price objective (down from $9.00) on shares of Geron in a research note on Thursday. Stifel Nicolaus lowered their price objective on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday. Needham & Company LLC decreased their price target on Geron from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Scotiabank decreased their price target on Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Geron has an average rating of "Moderate Buy" and an average target price of $5.68.

Geron Stock Performance

The firm has a fifty day simple moving average of $2.93 and a 200-day simple moving average of $3.77. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53.

Remove Ads

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Analysts forecast that Geron Co. will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Alternative Investment Advisors LLC. lifted its stake in shares of Geron by 13.3% in the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 2,612 shares during the period. Rovin Capital UT ADV lifted its stake in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 3,660 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Geron by 23.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 4,094 shares during the period. Xponance Inc. lifted its stake in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 4,829 shares during the period. Finally, US Bancorp DE lifted its stake in shares of Geron by 68.4% in the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 7,429 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.